The National Medicine Medicine Federation of Medicine, why did Hubei win Guangdong?

The market may not expect that the collection of Chinese medicine collection will also set up a national union -priced office.

On September 9th, the National Medicine Federation of Medicine issued the "Announcement of Procurement of the National Chinese Pharmaceutical Alliance (No. 1, 2022)", which officially launched the National Pharmaceutical Collection of Pharmaceuticals this year. This Liancai Office is located in Hubei. The first league collection scope includes 29 provinces and cities including Beijing, Tianjin, Hebei, and Shanxi.

Fujian and Hunan did not participate in the first national syntometer collection.

The form of "Liancai Office" was the first national drug collection organized by Shanghai. Since then, Tianjin has led the national high -value consumable collection. Nowadays, the Chinese patent medicine collection is a single column and handed over to Hubei to organize the industry.

Since the beginning of this year, four large -scale Chinese medicine collection has been carried out nationwide. In December 2021, Hubei organized a collection of Chinese medicine collection in 19 provinces and cities including Hebei and Hunan; Guangdong organized 6 provinces and cities, and Shandong and Beijing both organized the Chinese patent medicine collection in this province.

As a large province with drug circulation, Guangdong and Shandong have not been selected, but Hubei has won the organization of the nationwide union.

Why is it Hubei?

Win in "cheap"

For the first time, the national Chinese medicine collection selected 16 types of Chinese medicine with large clinical dosage, including compound spotted spots, compound thrombosis, Huasu, and Xin Keshu. The procurement cycle is 2 years and can be prolonged according to the situation. All public medical institutions in the alliance area must participate, and private hospitals and pharmacies with designated medical insurance are participated in accordance with local regulations.

The Hubei side did not disclose the specific rules of collecting collection. Some people with Chinese medicine companies told the Jianxian Bureau: "It is expected to refer to the first 19 provinces and cities of Hubei Organization."

From time to time, Guangdong is the first province in the country to propose a special collection of Chinese medicine. In September 2021, Guangdong proposed a collection plan for 58 varieties, hoping to participate in other provinces.

However, the above -mentioned people pointed out that the intensity of Guangdong's collection is worse than the subsequent Hubei Jizhi.

First of all, the provinces and cities covered by the Hubei Alliance have been wider.

The Guangdong Alliance has six major provinces in Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai; the Hubei Alliance includes 19 provinces. Therefore, if the nationwide section is organized, the experience of Hubei has more reference value.

Another key reason is that Hubei's bargaining is even more powerful.

From the perspective of the National Liancai Announcement, the official selection of the classification method used in Hubei Ji Cai. The product group is divided in accordance with the main functions and administration channels. Different dosage forms and specifications are not distinguished, and exclusive varieties are not distinguished.

The collection of Chinese medicine has always had a headache for the Medical Insurance Bureau. Due to the unstable output of raw materials and large cost changes, the prices of proprietary Chinese medicines are difficult to suppress. The exclusive variety is still high.

In the collection of Chinese medicines in Guangdong, non -exclusive variety treatment functions are classified, but the exclusive varieties are retained alone. The 36 well -known and exclusive varieties including compound Danshen Danshi Pills, Lianhua Qing Plague Capsules, and Brain -Heart Capsules finally talked about 30 in the end, with an average decrease of 21%, a decrease of 32.5%lower than the average variety.

Regardless of whether it is exclusive or not, the 19 provinces and cities organized by Hubei Organization have been bargaining. Harbin Pharmaceutical Group Traditional Chinese Medicine Second Factory's injection of Salviat and Jinshuibao Pharmaceuticals have lost their own classification preferential treatment and participated in the auction with ordinary products. In the end, the overall price reduction reached 42.27%.

It can be seen that the price of proprietary Chinese medicines dropped, and Hubei performed even better.

Local collection is the mainstream of the future

As early as August, a document issued by the Hubei Provincial Medical Insurance Bureau was circulated in the industry.

The document shows that Hubei Province will invite some provinces and cities to carry out the second batch of Sino -patent medicine collection work. Interestingly, this open procurement directory is exactly the same as the national collection.

In other words, the "Hubei Plan" has become a national plan.

This is different from the previous national collection. Generally speaking, the National Collection and Micro will be led by the National Medical Insurance Bureau and implemented nationwide. Taking the recent oral implant collection as an example, the leading province is Sichuan, a province of China -designated Chinese dental implants. In the past, the Tianjin National Medical Devices Union Office and the Shanghai National Pharmaceutical Union Office were as good as it.

If according to the idea of ​​Sichuan collection, it is likely to organize the nationwide patent patent medicine union.

According to the "Statistical Analysis Report of the Operation of the Drug Distribution Industry in 2021" released by the Ministry of Commerce, the total sales of the Chinese medicine category in 2021 were the highest in Guangdong, with 38.381 billion yuan, accounting for 10.24%in the country. From the perspective of market size, Guangdong seems to be more suitable for leading the nation's patent medicine.

However, Guangdong, with a greater market advantage, did not win this lead.

Regarding the collection of Chinese medicines, Lu Qingguo, a representative of the National People's Congress and the chairman of Chenguang Bio, has proposed that there are not enough provinces to cover the collection of Chinese medicines, there are fewer varieties, and they have not achieved sufficient price competition.

It can be seen that the price reduction and the breadth of coverage are the priority consideration of the National Medical Insurance Bureau to choose the organization. It turns out that Hubei, which has performed well in these two aspects, led the first national patent medicine for the first national medicine.

The success of Hubei has released a signal: the collection is inclined to the place.

In the future, the provincial -level alliance collection may become the main form of organization.At present, the National Pharmaceutical Collection has entered the renewal period one after another, and the decision -making right of renewal is completely put into various provinces.Some social concerns, such as dental implants, liver biochemical reagents, etc., are basically led by the provincial level to carry out the national alliance collection.Chen Jinfu, deputy director of the National Medical Insurance Bureau, has made it clear that "National Organization Collection is the collection of local alliances, and provincial -level alliance collection is the main body of centralized procurement."

Writing ｜ Yang Xixia

Edit ｜ Jiang Yun Jia Ting

Operation | Twenty -thirty

Illustration ｜ Visual China

####

- END -